Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that seven oral and four poster presentations detailing updated clinical and preclinical results generated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE